Business Wire

EpiEndo Pharmaceuticals Announces Launch of First-in-Human Clinical Trial of a Non-Antibiotic Macrolide for the Treatment of Chronic Inflammatory Airway Diseases

Share

EpiEndo Pharmaceuticals (www.epiendo.com), a clinical-stage biopharmaceutical company developing novel non-antibiotic macrolide therapeutics for the treatment of inflammatory disorders, announced today that the first subjects have been dosed in the Company's first-in-human phase I clinical trial of its lead candidate, EP395, at the Medicines Evaluation Unit (MEU) in Manchester, UK (clinicaltrials.gov identification number NCT04819854). The trial is led by Professor Dave Singh, Professor of Respiratory Pharmacology at the University of Manchester and Medical Director at MEU.

“I am delighted to say that our single ascending dose study has started and that the first six healthy subjects have been given a dose of EP395,” commented Dr. Ginny Norris, EpiEndo’s Chief Medical Officer. “The study will now continue with further single dosing and, later, multiple dosing. Dosing of our first subjects with EP395 is an important milestone for EpiEndo, as it brings us one step closer to offering a potentially meaningful therapeutic option to patients with COPD. This study will produce important early clinical data to guide our future development plans and continues to demonstrate EpiEndo’s leadership in development of non-antibiotic macrolides.”

EP395 is an orally active non-antibiotic macrolide therapeutic with potential to become a first-in-class treatment of chronic airway diseases, including chronic obstructive pulmonary disorder (COPD), asthma, bronchiectasis (BE), diffuse pan-bronchiolitis (DPB), as well as other inflammatory disorders. COPD is a chronic inflammatory disorder of the airway caused primarily by exposure to smoke and environmental pollution. EpiEndo is uniquely focused on restoration of epithelial barrier integrity as a causal underlying driver of disease pathophysiology, common across a range of inflammatory conditions.

"The successful treatment of chronic inflammatory airway diseases remains a challenge facing pulmonologists and a major opportunity exists for a safe, disease modifying, orally-available therapeutic,” said Professor Clive Page, OBE, Chairman of EpiEndo. “COPD has risen in incidence to become the third leading cause of death globally, while still today the standard of care provides only temporary, symptomatic relief. After a substantial pre-clinical programme demonstrating the potential of EP395, I am delighted to announce the start of the phase I clinical trial.”

The Company's distinguished scientific team is led by Chief Scientific Officer, Prof. Dr. Michael J. Parnham, a field-leading expert and a former Director of Preclinical Drug Development at GSK, and is supported by global key opinion leaders in the respiratory field.

“Independent of their valuable antibiotic properties, macrolides have potent, multimodal immunomodulatory properties, that have been well-known since their discovery in the 1950s, but their use for chronic conditions remains limited due to antimicrobial resistance concerns,” commented Prof. Dr. Parnham. “Importantly macrolides promote integrity of the lung epithelium as well as suppressing the neutrophilic inflammation that is clinically relevant to COPD, and which is generally resistant to the corticosteroid component of the current "triple therapy" standard of care. Our lead candidate, EP395, has been specifically optimised to eliminate antibiotic properties while accentuating anti-inflammatory effects of macrolides so that it can be widely deployed for long term respiratory conditions while avoiding antimicrobial resistance concerns.”

About EpiEndo Pharmaceuticals (www.epiendo.com)

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation.

EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs.

EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.

For more information, please visit www.epiendo.com

Forward-Looking Statements

This press release may contain certain forward-looking statements concerning the financial condition, results of operations and businesses of the Company. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements of future expectations that are based on management’s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. You should not place undue reliance on forward-looking statements. Each forward-looking statement speaks only as of the date of this presentation. The information in this presentation is subject to updating, completion, revision, further verification, and amendment without notice and the Company does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Maria Bech
CEO
E-mail: maria.bech@epiendo.com

EpiEndo Pharmaceuticals
E-mail: info@epiendo.com
Tel: [+354] 454 0090

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Reports First Quarter 2021 Results10.5.2021 22:19:00 CEST | Press release

International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the first quarter ended March 31, 2021. Management Commentary “We delivered solid first quarter financials, achieving top and bottom-line growth, against a strong year-ago comparison in our first quarter as a combined company,” said IFF Chairman and CEO Andreas Fibig. “Our results are indicative of strong execution by our global team and our best-in-class portfolio of industry-leading solutions. We are also encouraged by the progress we’ve made towards our integration efforts as we are on track to deliver our previously communicated objectives.” IFF Executive Vice President and CFO, Rustom Jilla commented, “We are pleased with how we've started the year with the first quarter’s sales, operating expenses, profitability and debt leverage all ending better than we had expected. At the core of our performance was strong cost discipline and a focus on cash generation, which enabled us to make faster progress

Rimini Street Announces Fiscal First Quarter 2021 Financial Results10.5.2021 22:05:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced results for the first quarter ended March 31, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005029/en/ Rimini Street Announces Fiscal First Quarter 2021 Financial Results (Graphic: Business Wire) “For the first quarter, we remain on track to achieve our strategic growth plan to achieve $1 billion in annual revenue by 2026. We achieved record revenue of $87.9 million, up 12.6% year over year, a record active client count of 2,550, up 22.8% year over year, ended the quarter with strong billings growth of 24.2% and delivered a gross margin greater than 61%,” stated Seth A. Ravin, Rimini Street co-founder, CEO and chairman of the board. “We also continued making investments to take advantage of growi

SpeeDx Receives CARB-X Funding to Develop Rapid Point-of-Care Diagnostic10.5.2021 22:00:00 CEST | Press release

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting research and development to address the rising threat of drug-resistant bacteria. SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones. Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae, while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments. Chlamydia (CT) and gonorrhea (NG) are globally significant sexually transmitted infections with serious health complications if left untreated,1 and AMR NG is an urgent public health threat.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510

SentinelOne Named a Leader in the 2021 Gartner Magic Quadrant for Endpoint Protection Platforms10.5.2021 18:12:00 CEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced it has been positioned by Gartner as a Leader in the 2021 Magic Quadrant for Endpoint Protection Platforms1. SentinelOne believes the placement is a testament to the company’s innovative Singularity XDR platform and scaled go-to-market execution in record time. We believe this accomplishment signifies unrivaled product-market fit, innovation, and superb customer experience across a diverse set of customer profiles. “Modern society is digital, and every place where data resides is vulnerable. Human-powered products simply cannot keep up with the exponentially growing threat landscape. Our AI-powered technology is the automated solution to modern day cyberattacks,” said Tomer Weingarten, CEO and Co-founder, SentinelOne. “We believe being named a Leader in the Gartner Magic Quadrant validates our approach and aligns with the market traction we’re experiencing. I am proud our team continues to deliver innovation, s

ESI Group Launches a “No Meeting Day” to Protect Its Employees Work-life Balance and Restore the Importance of Taking Time10.5.2021 18:00:00 CEST | Press release

ESI Group (Paris:ESI): An unbalanced equation A year ago, in the wake of COVID-19, companies began adapting to ensure the continuity of their activities during lockdown. With people bound to their homes, the opportunity to create social connections, in a professional or personal context, has strongly been affected. Indeed, as a major component of the life of many citizens, offices and workplaces are and remain a main outlet for socialization. In order to counterbalance this change, companies have utilized tools, like digital meetings, to continue connecting employees to maintain team spirit and a sense of belonging. Companies became one of the last remaining social links things when everything else was put on hold. As a result, teams’ agendas have filled up; meetings now punctuate the day, causing stress, taking away the time needed to perform various tasks and reducing focus time, pushing the workday into the evening or even the weekend. Time to breathe and take a step back: “No meeti

Schlumberger and NOV Announce Collaboration to Accelerate Adoption of Automated Drilling Solutions10.5.2021 16:00:00 CEST | Press release

Schlumberger and NOV announced today a collaboration to accelerate automated drilling solutions adoption by oil and gas operators and drilling contractors. The agreement will enable customers to combine Schlumberger surface and downhole drilling automation solutions with NOV’s rig automation platform to deliver superior well construction performance. This integrated offering enables the automation of manual workflows, improving safety, decision making, consistency, and efficiency in drilling operations. “We are pleased to collaborate with NOV and to integrate their rig automation interface with our drilling automation solutions to unlock higher performance for operators and drilling contractors. Leveraging downhole and surface automation applications, we can deliver enhancements in operations safety and efficiency, and deliver top-quartile wells for our customers consistently,” comments Olivier Le Peuch, CEO, Schlumberger. “This partnership will help accelerate customers’ adoption of d

Dahua Technology Unveils Upgraded WizMind to Enhance AI Experience10.5.2021 15:45:00 CEST | Press release

Dahua Technology, a world-leading video-centric smart IoT solution and service provider, has recently released its upgraded WizMind series, offering a comprehensive project-oriented product portfolio and flexible AI solutions that focus on human, vehicle, object and thermal technology to empower vertical markets with enhanced AI experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005414/en/ Dahua Technology’s Upgraded WizMind Series (Graphic: Business Wire) Human-based Applications Adopting topnotch AI chip and algorithms, the upgraded human-based WizMind solution includes privacy protection 2.0, face recognition 2.0, human video metadata 2.0 and other advanced AI performance to enable timely responses to incidents while providing accurate customer flow, crowd density, target direction, etc. to assist in further business analysis. Privacy Protection 2.0 offers additional occlusion options (irregular polygons, mo